ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print December 5, 2007
Eur Respir J 2007, doi:10.1183/09031936.00119007
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
31/3/579    most recent
09031936.00119007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brouillard, C.
Right arrow Articles by Maltais, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brouillard, C.
Right arrow Articles by Maltais, F.

ORIGINAL ARTICLE

Endurance Shuttle Walking Test: Responsiveness to Salmeterol in COPD

C. Brouillard 1, V. Pepin 2, J. Milot 1, Y. Lacasse 1, F. Maltais 1*

1 Centre de recherche, Hôpital Laval, Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval, Québec, Canada
2 Centre de recherche, Hôpital du Sacré-Coeur de Montréal, Montréal, Canada

* To whom correspondence should be addressed. E-mail: francois.maltais{at}med.ulaval.ca.


  Abstract

Few studies have shown that the endurance shuttle walking test (ESWT) is responsive to treatment in patients with chronic obstructive pulmonary disease (COPD). This exercise test needs to be further investigated because of its relevance for activity of daily living.

To evaluate, in patients with COPD, the responsiveness of the endurance shuttle walk to detect improvement in walking performance after single dose of salmeterol.

In a randomised, double-blind, placebo-controlled, crossover trial, 20 patients with COPD performed two ESWT at 80% of peak capacity 2.5 hours after inhaling either a placebo or 50µg of salmeterol. Cardiorespiratory parameters were monitored during each walking test. Inspiratory capacities and Borg ratings for dyspnoea were obtained every other minute throughout the tests.

Compared to placebo, salmeterol produced a significant change in lung function and a significant improvement in walking performance ({Delta} time: 117 (96) seconds, p=0.02; {Delta} distance: 160 (125) meters, p=0.02). At isotime, a significant reduction in dyspnoea was observed after bronchodilation.

Bronchodilation with salmeterol reduced dyspnoea during walking and improved walking capacity in patients with COPD. These findings provide further support for the use of the ESWT as an evaluative tool in COPD.

Keywords:  Bronchodilators, chronic obstructive pulmonary disease, endurance, exercise capacity, exercise testing, salmeterol




This article has been cited by other articles:


Home page
 ChestHome page
J. A. Murray, L. A. Waterman, J. Ward, J. C. Baird, and D. A. Mahler
Perceptual and Physiologic Responses During Treadmill and Cycle Exercise in Patients With COPD
Chest, February 1, 2009; 135(2): 384 - 390.
[Abstract] [Full Text] [PDF]

Home page
 ACCP Pulmonary Med Brd RevHome page
D. D. Marciniuk
Cardiopulmonary Exercise Testing
ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 113 - 128.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the European Respiratory Society.